Pros | - | - | ||
Cons | - | - |
INDMoney rank | - | - | ||
Category,Subcateogry | Equity,Index Funds | Equity,Index Funds | ||
Fund Age | 2 Years | 1 Years | ||
Fund Size | 91 Cr | 4007 Cr | ||
Min Investment | SIP ₹1000 Lumpsum ₹1000 | SIP ₹500 Lumpsum ₹500 | ||
Expense Ratio | 0.37% | 0.42% | ||
Exit Load | 0% | 1% | ||
Benchmark Index | Nifty Pharma TR INR | Nifty India Defence TR INR |
No of Holdings | 22 | 20 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (23.72%) Divi's Laboratories Ltd (11.01%) Cipla Ltd (10.81%) Dr Reddy's Laboratories Ltd (10.01%) Lupin Ltd (6.2%) | Bharat Electronics Ltd (18.61%) Hindustan Aeronautics Ltd Ordinary Shares (18%) Solar Industries India Ltd (16.07%) Mazagon Dock Shipbuilders Ltd (8.74%) Bharat Dynamics Ltd Ordinary Shares (7.61%) | ||
No of Sectors | 1 | 4 | ||
Top 3 Sectors | Health (100%) | Industrial (77.42%) Basic Materials (16.93%) Tech (4.55%) | ||
Equity % | 99.9% | 99.94% | ||
Debt % | - | - | ||
P/E | 31.21 | 51.84 | ||
P/B | 4.81 | 11.61 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.99% | -3.42% | ||
3-Month Return | 8.79% | 35.61% | ||
6-Month Return | -0.31% | 36.4% | ||
1-Year Return | 8.35% | 2.61% | ||
3-Year Return | - | - | ||
5-Year Return | - | - |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | ICICI Prudential Nifty Pharma Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Motilal Oswal Nifty India Defence Index Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Nishit Patel | Swapnil Mayekar |